VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Vaccine Mechanisms
VaximmutorDB
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

F. tularensis FopB Protein Vaccine
Vaccine Information
  • Vaccine Name: F. tularensis FopB Protein Vaccine
  • Target Pathogen: Francisella tularensis
  • Target Disease: Tularemia
  • Vaccine Ontology ID: VO_0004034
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: .5 μg recombinant FopB protein
  • FopB gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: CpG DNA vaccine adjuvant
    • Adjuvant name: CpG DNA vaccine adjuvant
    • VO adjuvant ID: VO_0001237
    • Description: 10 μg of CpG oligodeoxynucleotide (5′-TCCATGACGTTCCTGACGTT-3′; Operon, Huntsville, AL)
  • Immunization Route: intranasal immunization
Host Response

Mouse Response

  • Host Strain: C57BL/6 and HLA-DR4 tg
  • Vaccination Protocol: mice were anesthetized i.n. with 3% isoflurane by use of a rodent anesthesia system and were immunized i.n. on day 0 with 7.5 μg rFopB in 25 μl of sterile PBS. This was accompanied by immunization with 10 μg of CpG oligodeoxynucleotide on days −1, 0, and +1. Mice were boosted once on day 14 with the same amount of antigen (Yu et al., 2010).
  • Challenge Protocol: Mice were challenged i.n. with approximately 3.5 × 104 CFU (∼5 50% lethal doses [LD50s]) of LVS on day 30 (Yu et al., 2010).
  • Efficacy: Intranasal vaccination of mice with rFopB conferred 50% protection (P < 0.05) against an otherwise lethal pulmonary challenge of 5 LD50s of LVS (3.5 × 104 CFU) in both C57BL/6 and HLA-DR4 tg mice compared with the protection conferred to LVS-challenged mock-vaccinated mice, all of which succumbed to the infection by day 10 (Yu et al., 2010).
  • Host Ifng (Interferon gamma) response
    • Description: Spleens were collected at 14 days postvaccination, and single cells were prepared and assayed for FopB- and LVS-induced IFN-γ production. Differences in IFN-γ stimulation between rFopB- and mock-vaccinated mice were significant (Yu et al., 2010).
    • Detailed Gene Information: Click Here.
References
Yu et al., 2010: Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clinical and vaccine immunology : CVI. 2010; 17(2); 215-222. [PubMed: 20016043].